Since the start of the pandemic, fear of drug shortages have been top of mind for companies that source active pharmaceutical ingredients from China. A recent FiercePharma article noted that India, the world’s largest maker of generic drugs, is investing in alternatives to Chinese APIs. The Indian government is establishing a $1.3B fund to produce more APIs domestically. The fund will cover infrastructure and financial incentives for up to 20% of incremental sales value over a period of eight years.
Quick Hits: India Weans Itself off Chinese APIs
India is investing $1.3B to decrease its dependence on Chinese APIs amid supply concerns related to the coronavirus outbreak.
Mar 27, 2020
How to Honor a Leader
Induction into the Packaging & Processing Hall of Fame is the highest honor in our industry. Submit your leader to be considered for the Class of 2024 now through June 10th. New members will be inducted at PACK EXPO International in Chicago.
Read MoreDiscover the right packaging solutions for life sciences in Philadelphia
Explore innovative packaging and supply chain solutions for the life sciences at the largest PACK EXPO East in history, March 18–20. Get ideas from 400+ top exhibitors and connect with colleagues and industry experts—all in one convenient location!
Read More